EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

Lori A. Ehrlich, Ho Yeon Chung, Irene Ghobrial, Sun Jin Choi, Francesca Morandi, Simona Colla, Vittorio Rizzoli, G. David Roodman, Nicola Giuliani

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Bone destruction in multiple myeloma is characterized both by markedly increased osteoclastic bone destruction and severely impaired osteoblast activity. We reported that interleukin-3 (IL-3) levels are increased in bone marrow plasma of myeloma patients compared with healthy controls and that IL-3 stimulates osteoclast formation. However, the effects of IL-3 on osteoblasts are unknown. Therefore, to determine if IL-3 inhibits osteoblast growth and differentiation, we treated primary mouse and human marrow stromal cells with IL-3 and assessed osteoblast differentiation. IL-3 inhibited basal and bone morphogenic protein-2 (BMP-2)-stimulated osteoblast formation in a dose-dependent manner without affecting cell growth. Importantly, marrow plasma from patients with high IL-3 levels inhibited osteoblast differentiation, which could be blocked by anti-IL-3. However, IL-3 did not inhibit osteoblast differentiation of osteoblastlike cell lines. In contrast, IL-3 increased the number of CD45+ hematopoietic cells in stromal-cell cultures. Depletion of the CD45+ cells abolished the inhibitory effects of IL-3 on osteoblasts, and reconstitution of the cultures with CD45+ cells restored the capacity of IL-3 to inhibit osteoblast differentiation. These data suggest that IL-3 plays a dual role in the bone destructive process in myeloma by both stimulating osteoclasts and indirectly inhibiting osteoblast formation.

Original languageEnglish (US)
Pages (from-to)1407-1414
Number of pages8
JournalBlood
Volume106
Issue number4
DOIs
StatePublished - Aug 15 2005
Externally publishedYes

Fingerprint

Interleukin-3
Osteoblasts
Multiple Myeloma
Bone
Bone and Bones
Bone Marrow
Osteoclasts
Stromal Cells
Cell culture
Plasmas
Cell growth
Growth
Cell Culture Techniques

ASJC Scopus subject areas

  • Hematology

Cite this

Ehrlich, L. A., Chung, H. Y., Ghobrial, I., Choi, S. J., Morandi, F., Colla, S., ... Giuliani, N. (2005). EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 106(4), 1407-1414. https://doi.org/10.1182/blood-2005-03-1080

EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. / Ehrlich, Lori A.; Chung, Ho Yeon; Ghobrial, Irene; Choi, Sun Jin; Morandi, Francesca; Colla, Simona; Rizzoli, Vittorio; Roodman, G. David; Giuliani, Nicola.

In: Blood, Vol. 106, No. 4, 15.08.2005, p. 1407-1414.

Research output: Contribution to journalArticle

Ehrlich, LA, Chung, HY, Ghobrial, I, Choi, SJ, Morandi, F, Colla, S, Rizzoli, V, Roodman, GD & Giuliani, N 2005, 'EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma', Blood, vol. 106, no. 4, pp. 1407-1414. https://doi.org/10.1182/blood-2005-03-1080
Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S et al. EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005 Aug 15;106(4):1407-1414. https://doi.org/10.1182/blood-2005-03-1080
Ehrlich, Lori A. ; Chung, Ho Yeon ; Ghobrial, Irene ; Choi, Sun Jin ; Morandi, Francesca ; Colla, Simona ; Rizzoli, Vittorio ; Roodman, G. David ; Giuliani, Nicola. / EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. In: Blood. 2005 ; Vol. 106, No. 4. pp. 1407-1414.
@article{e14579543df24563a8c0854042ca9671,
title = "EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma",
abstract = "Bone destruction in multiple myeloma is characterized both by markedly increased osteoclastic bone destruction and severely impaired osteoblast activity. We reported that interleukin-3 (IL-3) levels are increased in bone marrow plasma of myeloma patients compared with healthy controls and that IL-3 stimulates osteoclast formation. However, the effects of IL-3 on osteoblasts are unknown. Therefore, to determine if IL-3 inhibits osteoblast growth and differentiation, we treated primary mouse and human marrow stromal cells with IL-3 and assessed osteoblast differentiation. IL-3 inhibited basal and bone morphogenic protein-2 (BMP-2)-stimulated osteoblast formation in a dose-dependent manner without affecting cell growth. Importantly, marrow plasma from patients with high IL-3 levels inhibited osteoblast differentiation, which could be blocked by anti-IL-3. However, IL-3 did not inhibit osteoblast differentiation of osteoblastlike cell lines. In contrast, IL-3 increased the number of CD45+ hematopoietic cells in stromal-cell cultures. Depletion of the CD45+ cells abolished the inhibitory effects of IL-3 on osteoblasts, and reconstitution of the cultures with CD45+ cells restored the capacity of IL-3 to inhibit osteoblast differentiation. These data suggest that IL-3 plays a dual role in the bone destructive process in myeloma by both stimulating osteoclasts and indirectly inhibiting osteoblast formation.",
author = "Ehrlich, {Lori A.} and Chung, {Ho Yeon} and Irene Ghobrial and Choi, {Sun Jin} and Francesca Morandi and Simona Colla and Vittorio Rizzoli and Roodman, {G. David} and Nicola Giuliani",
year = "2005",
month = "8",
day = "15",
doi = "10.1182/blood-2005-03-1080",
language = "English (US)",
volume = "106",
pages = "1407--1414",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

AU - Ehrlich, Lori A.

AU - Chung, Ho Yeon

AU - Ghobrial, Irene

AU - Choi, Sun Jin

AU - Morandi, Francesca

AU - Colla, Simona

AU - Rizzoli, Vittorio

AU - Roodman, G. David

AU - Giuliani, Nicola

PY - 2005/8/15

Y1 - 2005/8/15

N2 - Bone destruction in multiple myeloma is characterized both by markedly increased osteoclastic bone destruction and severely impaired osteoblast activity. We reported that interleukin-3 (IL-3) levels are increased in bone marrow plasma of myeloma patients compared with healthy controls and that IL-3 stimulates osteoclast formation. However, the effects of IL-3 on osteoblasts are unknown. Therefore, to determine if IL-3 inhibits osteoblast growth and differentiation, we treated primary mouse and human marrow stromal cells with IL-3 and assessed osteoblast differentiation. IL-3 inhibited basal and bone morphogenic protein-2 (BMP-2)-stimulated osteoblast formation in a dose-dependent manner without affecting cell growth. Importantly, marrow plasma from patients with high IL-3 levels inhibited osteoblast differentiation, which could be blocked by anti-IL-3. However, IL-3 did not inhibit osteoblast differentiation of osteoblastlike cell lines. In contrast, IL-3 increased the number of CD45+ hematopoietic cells in stromal-cell cultures. Depletion of the CD45+ cells abolished the inhibitory effects of IL-3 on osteoblasts, and reconstitution of the cultures with CD45+ cells restored the capacity of IL-3 to inhibit osteoblast differentiation. These data suggest that IL-3 plays a dual role in the bone destructive process in myeloma by both stimulating osteoclasts and indirectly inhibiting osteoblast formation.

AB - Bone destruction in multiple myeloma is characterized both by markedly increased osteoclastic bone destruction and severely impaired osteoblast activity. We reported that interleukin-3 (IL-3) levels are increased in bone marrow plasma of myeloma patients compared with healthy controls and that IL-3 stimulates osteoclast formation. However, the effects of IL-3 on osteoblasts are unknown. Therefore, to determine if IL-3 inhibits osteoblast growth and differentiation, we treated primary mouse and human marrow stromal cells with IL-3 and assessed osteoblast differentiation. IL-3 inhibited basal and bone morphogenic protein-2 (BMP-2)-stimulated osteoblast formation in a dose-dependent manner without affecting cell growth. Importantly, marrow plasma from patients with high IL-3 levels inhibited osteoblast differentiation, which could be blocked by anti-IL-3. However, IL-3 did not inhibit osteoblast differentiation of osteoblastlike cell lines. In contrast, IL-3 increased the number of CD45+ hematopoietic cells in stromal-cell cultures. Depletion of the CD45+ cells abolished the inhibitory effects of IL-3 on osteoblasts, and reconstitution of the cultures with CD45+ cells restored the capacity of IL-3 to inhibit osteoblast differentiation. These data suggest that IL-3 plays a dual role in the bone destructive process in myeloma by both stimulating osteoclasts and indirectly inhibiting osteoblast formation.

UR - http://www.scopus.com/inward/record.url?scp=23744507989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744507989&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-03-1080

DO - 10.1182/blood-2005-03-1080

M3 - Article

C2 - 15878977

AN - SCOPUS:23744507989

VL - 106

SP - 1407

EP - 1414

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -